Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician",Pembrolizumab Axitinib,"Pembrolizumab and axitinib, first line treatment of advanced clear cell renal cell carcinoma",Pembrolizumab Axitinib (Keytruda Inlyta),Only if cost neutral or cost saving,Community and Hospital,Oncology Agents and Immunosuppressants
